Apo-2 ligand

Details Apo-2 ligand Apo-2 ligand

2007-10-23

2007-10-23

Romeo, David (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S149000, C514S248000, C514S283000, C530S350000, C530S402000, C540S478000, C544S313000, C544S317000, C930S140000

Reexamination Certificate

active

10861685

ABSTRACT:
A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.

REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4206226 (1980-06-01), Gale et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4342566 (1982-08-01), Theofilopoulos et al.
patent: 4399216 (1983-08-01), Axel et al.
patent: 4419446 (1983-12-01), Howley et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4601978 (1986-07-01), Karin
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4676980 (1987-06-01), Segal et al.
patent: 4736866 (1988-04-01), Leder et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4870009 (1989-09-01), Evans et al.
patent: 4965199 (1990-10-01), Capon et al.
patent: 5010182 (1991-04-01), Brake et al.
patent: 5149319 (1992-09-01), Unger
patent: 5364934 (1994-11-01), Drayna et al.
patent: 5457187 (1995-10-01), Gmeiner et al.
patent: 5484399 (1996-01-01), DiResta et al.
patent: 5688773 (1997-11-01), Chiocca et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5773476 (1998-06-01), Chen et al.
patent: 6284236 (2001-09-01), Wiley et al.
patent: 2002/0115613 (2002-08-01), Kumar
patent: 2005/0089958 (2005-04-01), Ashkenazi et al.
patent: 2225378 (1997-01-01), None
patent: 266710 (1989-04-01), None
patent: 0003089 (1979-07-01), None
patent: 036776 (1981-09-01), None
patent: 073657 (1983-03-01), None
patent: 117058 (1984-08-01), None
patent: 117060 (1984-08-01), None
patent: 164965 (1985-12-01), None
patent: 307247 (1989-03-01), None
patent: 321196 (1989-06-01), None
patent: 362179 (1990-04-01), None
patent: 417563 (1991-03-01), None
patent: 2211504 (1989-07-01), None
patent: WO87/05330 (1987-09-01), None
patent: WO89/05859 (1989-06-01), None
patent: WO90/13646 (1990-11-01), None
patent: WO91/00358 (1991-01-01), None
patent: WO91/00360 (1991-01-01), None
patent: WO91/08291 (1991-06-01), None
patent: WO92/20373 (1992-11-01), None
patent: WO93/08829 (1993-05-01), None
patent: WO94/04679 (1994-03-01), None
patent: WO94/04690 (1994-03-01), None
patent: WO94/29348 (1994-12-01), None
patent: WO95/10540 (1995-04-01), None
patent: WO95/11301 (1995-04-01), None
patent: WO95/31544 (1995-11-01), None
patent: WO97/01633 (1997-01-01), None
patent: WO97/25428 (1997-07-01), None
patent: WO97/33899 (1997-09-01), None
patent: WO97/46686 (1997-12-01), None
patent: WO 02/053727 (2002-07-01), None
patent: WO 02/069995 (2002-09-01), None
U.S. Appl. No. 08/496,632, Wiley et al.
U.S. Appl. No. 08/548,368, Wiley et al.
Aggarwal et al., “Human Tumor Necrosis Factor”Journal of Biological Chemistry260(4) :2345-2354 (1985).
Alberts et al.Molecular Biology of the Cell, 3RD edition, New York:Garland Publishing, Inc. pp. 119.
Alberts et al.Molecular Biology of the Cell, 3rd edition, New York:Garland Publishing, Inc. pp. 415-416 (1994).
Alberts et al.Molecular Biology of the Cell, New York, NY:Garland Publishing, Inc. pp. 264-266 (Jan. 1983).
Alberts et al., “Molecular Biology of the Cell”, ., New York, NY:Garland Publishing, Inc. pp. 1267 (Jan. 1994).
Amakawa et al., “The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells”Symposium on Programmed Cell Death(Abstract No. 10), Cold Spring Harbor Laboratory (1995).
Antibodies, A Laboratory Manual, E. Harlow and D. Lane, p. 342, (1988).
Aplin and Wriston, “Preparation, Properties, and Applications of Carbohydrates Conjugates of Protein and Lipids”CRC Crit. Rev. Biochem.10(4) :259-306 (1981).
Ashkenazi and Chamow, “Immunoadhesins: An Alternative to Human Monoclonal Antibodies”Methods: A Companion to Methods in Enzymology8:104-115 (1995).
Ashkenazi et al., “Induction of Apoptosis by APO-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family”European Cytokine Network7:159 (1996).
Ashkenazi et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin”Proc. Natl. Acad. Sci.88:10535-10539 (1991).
Autologue Bone Marrow Transplantation: Proceedings of the Third International Symposium, Dicke et al., University of Texas M.D. Anderson Hospital (1987).
Banerji et al., “A Lymphocyte-specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes”Cell33:729-740 (Jul. 1983).
Barr and Tomei, “Apoptosis and Its Role in Human Disease”Bio/Technology12:487-493 (1994).
Bianchi et al., “Transformation of the yeastKluyveromyces lactisby New Vectors Derived from the 1.6 μm Circular Plasmid pXD1”Curr. Genet. 12:185-192 (1987).
“BLAST Results A-1—A-36” (GenBank), Date Unknown.
“BLAST Results B-1—B-25” (Dayhoff), Date Unknown.
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes”The Journal of Immunology147(1) :86-95 (1991).
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle”Genome Researchvol. 10:398-400 (2000).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”Science247:1306-1310 (1990).
Bradley, “Production and Analysis of Chimaeric Mice”Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed., IRL, Oxford, Chapter 5, pp. 113-151 (1987).
Brockhaus et al., “Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies.”Proc. Natl. Acad. Sci. USA87:3127-3131 (1990).
Brodeur et al., “Mouse-Human Myeloma Partners for the Production of Heterohybridomas”Monoclonal Antibody Production Techniques and Applications, New York:Marcel Dekker, Inc. pp. 51-63 (1987).
Brojatsch et al., “CAR1, A TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis.”Cell. 87:845-855 (1996).
Browning et al., “Lymphotoxin β, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface”Cell72:847-856 (1993).
Bruggemann et al., “Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals”Year in Immunology7:33-40 (1993).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue”Journal of Cell Biology111:2129-2138 (1990).
Byrn et al., “Biological Properties of a CD4 Immunoadhesin”Nature344:667-670 (Apr. 12, 1990).
Canaani et al., “Regulated Expression of Human Interferon β1Gene After Transduction into Cultured Mouse and Rabbit Cells”Proc. Natl. Acad. Sci. USA79:5166-5170 (Sep. 1982).
Carter et al., “Humanization of an Anti-p185HER2Antibody For Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89:4285-4289 (May 1992).
Chamow et al., “A Humanized, Bispecific Immunoadhesin-Antibody That Retargets CD3+Effectors to Kill HIV-1-Infected Cells”Journal of Immunology153:4268-4280 (1994).
Chang et al., “Phenotypic Expression inE. coliof a DNA Sequence Coding for Mouse Dihydrofolate Reductases”Nature275:617-624 (Oct. 19, 1978).
Chemotherapy Service Ed., M. C. Perry, Baltimore, MD:Williams & Wilkins (1992).

Affiliated with

Also associated with

Rating

Apo-2 ligand does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Apo-2 ligand, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apo-2 ligand will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3887341